Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407027 | 0.84 | TACR1 (0.52) | TACR1DRD2DRD3SIGMAR1GRIN1 | |
| SCHEMBL6409782 | 0.81 | TACR1 (0.53) | TACR1GAAKMT2A | |
| SCHEMBL6408949 | 0.78 | CHRM2 (0.47) | DRD2DRD3SIGMAR1GAALMNA | |
| SCHEMBL29960543 | 0.75 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL8314144 | 0.75 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL8314148 | 0.75 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL350298 | 0.75 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL6410991 | 0.75 | TACR1 (0.43) | TACR1DRD2DRD3SIGMAR1GRIN1 | |
| SCHEMBL6408807 | 0.73 | GAA (0.42) | GAALMNAMAPK1KMT2A | |
| SCHEMBL1617423 | 0.71 | TACR1 (0.56) | TACR1SIGMAR1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885DRD2 136/4885DRD3 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.